Views & Analysis | Perspectives on pharma industry issues

Oncology

pharmaphorum podcast Episode 286, Kate Estep, Flatiron Health

Closing the global evidence gap in oncology, with Flatiron H...

Kate Estep discusses Flatiron’s AI-powered oncology intelligence platform, Telescope, and how AI tools are changing research decisions.

R&D

Life sciences real estate: Beyond labs

Growth in biotechnology, pharmaceutical R&D, and advanced therapies is driving demand for specialist laboratory space.

R&D

Inspection readiness is now a commercial question

Manufacturers of advanced therapies are discovering that a digital quality system does more than satisfy inspectors.

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

Pharmacy and clinical research: the pharmaphorum podcast

In the latest episode of the pharmaphorum podcast, pharmaphorum’s web editor Catherine Longworth speaks to Gerald Finken, the founder and CEO of RxE2.

Views & Analysis

Climate change: The elephant in the waiting room of health

Pharma has both an opportunity and a responsibility to do its part in tackling climate change – and the time to act is now, according to speakers at a recent event.

Views & Analysis

Deep Dive: Oncology 2021

This has probably been the toughest year for oncology researchers in memory.

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.